BOC Sciences Continues to Broaden Its Inhibitor Range for Researchers
SHIRLEY, NY, UNITED STATES - May 29, 2019 - As one of the world's leading chemical suppliers, BOC Sciences announces to continuously broaden its small molecule inhibitor range in response to an increasingly urgent need to find a cure for some major diseases that are inflicting the human beings.
Small-molecule inhibitors, including their agonists and modulators, are a well-established class of potential useful drugs. The last two decades have seen its wide and deep application into all kinds of fields of medical and pharmaceutical research, such as neurological disease, inflammation, infection, cardiovascular and blood disease, cancer, metabolic disease and so on.
As promising therapeutic molecules for the treatment of a number of diseases, small-molecule inhibitors can be used in conjunction with other treatments, such as RNA interference (RNAi), says Prof. Jones, a senior scientist from BOC Sciences. Among all the conjugation methods, antibody drug conjugate is extensively researched, which consists of an antibody, a cytotoxic drug, and a linker that attaches the two. ADCs presents to the industry a broadly applicable method to increase the antitumor activity of antibodies and at the same time, improve the tumor-to-normal tissue selectivity of chemotherapy.
However, it is still a difficulty as to how to identify the most specific small-molecule inhibitor associated with a certain disease. Our scientists provide some guidelines to help you identify the optimized inhibitors with high affinity for their intended targets, and they are: check the related reference to see if they have already been researched by other people and if their selectivity and potency as drugs or as tools for chemical biology research have been specified; assess whether the inhibitor suppress the target in vitro; measure effectiveness of the inhibitor; observe if there are analogs inhibit the intended target as sometimes similar inhibitors that share the same scaffold have the same rank order potency on cells that they have in the biochemical assay; use a negative or positive control in each experiment, continuously explained Mr. Jones.
After the enlargement of this inhibitor product line, a relatively more comprehensive collection of therapeutic inhibitors are now available, including antiparasitic inhibitor, angiotensin receptor inhibitor, arp2/3 complex inhibitor, cannabinoid receptor inhibitor, CaSR inhibitor, checkpoint kinase inhibitor, chloride channel inhibitor, ALK inhibitor, Cdc7 inhibitor,cell adhesion molecules inhibitor, CFTR inhibitor, CETP inhibitor, CENP-E inhibitor and much more.
To know more about these chemicals, please visit https://www.bocsci.com/inhibitor-list-84.html or email at account@bocsci.com.
About BOC Sciences
Starting from 2007 as a small chemical provider for industry and academia, BOC Sciences never ceases its step of moving forward. In the last decade, its business range has largely been expanded. In addition to offering a broad range of high quality chemicals like inhibitors, ADC linkers, impurities, APIs, metabolites, BOC Sciences also focuses on an integrated service related to drug discovery, R&D, hoping to assist scientists and researchers in addressing the now major disease threats facing humankind like cancer, Alzheimer's.